Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

LBBAP Versus ILR in Patients With New-Onset LBBB and Moderately Reduced LVEF After TAVI (LBB(AP)TAVI)

13 november 2026 uppdaterad av: University Hospital, Clermont-Ferrand

Comparison of Left Bundle Branch Area Pacing (LBB(AP)) and Implantable Loop Recorder (ILR) in Patients With New-onset Left Bundle Branch Block and Moderately Reduced LVEF After Transcatheter Aortic Valve Implantation (TAVI): A Randomized Multicenter Study.

Patients with new-onset complete LBBB (QRS > 120 ms, persisting > 24 h after TAVI) and moderately reduced LVEF (35-50%) will be screened in participating centers.

Eligible patients will be centrally randomized 1:1 (stratified by center and atrial fibrillation (yes/no)) to either:

  • Experimental arm: Left bundle branch area pacing (LBB(AP)) with Biotronik pacemaker and dedicated conduction system pacing leads.
  • Control arm: Implantable loop recorder (ILR, Biotronik BIOMONITOR IV) for rhythm monitoring.

The occurrence of the following events within 12 months of randomization will be evaluated: hospitalization for heart failure, syncope or hemodynamically significant dizziness, or high-grade atrioventricular conduction disturbance.

The impact of LBB(AP) compared to ILR monitoring will be evaluated at 6, 12, 24, and 36 months regarding: incidence of atrial fibrillation; incidence of non-sustained ventricular tachycardia; evolution of left ventricular ejection fraction; quality of life; hospitalizations; mortality; medico-economic outcomes; qccurrence of high-grade AV conduction disorders beyond 12 months; omplications related to pacemaker or ILR implantation; unscheduled pacemaker implantation in the ILR group.

Patients will be monitored following a regular schedule that includes clinical visits, transthoracic echocardiography , ECG, remote device monitoring, and EQ-5D at 6, 12, 24 and 36 months.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

700

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Angers, Frankrike, 49000
        • CHU d'Angers
        • Huvudutredare:
          • Antoine POIRIER
      • Clermont-Ferrand, Frankrike, 63000
      • Dijon, Frankrike, 21000
        • CHU de DIJON
        • Huvudutredare:
          • Fabien GARNIER

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Patients with new-onset complete left bundle branch block (LBBB) defined as QRS duration >120 ms, occurring after TAVI and persisting for >24 hours on ECG. New-onset complete LBBB will be confirmed by QRS duration >120 ms together with standard morphological criteria (broad, notched or slurred R waves in leads I, aVL, V5 and V6, with absence of Q waves in V5-V6), assessed by the site cardiologist and confirmed by the adjudication committee, in line with current ESC and ACC/AHA/HRS recommendations.
  2. Left ventricular ejection fraction (LVEF) between 35% and 50%, assessed within one month before TAVI, in a stable hemodynamic state.
  3. Patients implanted with a self-expanding or balloon-expandable valve.
  4. Age ≥ 18 years.
  5. TAVI procedure performed according to current ESC guidelines. The applicable reference is the 2025 ESC/EACTS Guidelines for the management of valvular heart disease (Praz, et al. Eur Heart J. (2025) 46, 4635-4736), or any subsequent official ESC update in force at the time of each patient's procedure.
  6. Life expectancy > 1 year.
  7. Affiliation to a social security scheme
  8. Written informed consent provided before study enrollment.

Exclusion Criteria:

  1. Permanent pacemaker implantation (PPI) before TAVI.
  2. Complete atrioventricular block after TAVI leading to immediate PPI.
  3. Permanent pacemaker implantation after TAVI for another indication (non-protocol).
  4. Pre-existing LBBB before TAVI.
  5. Trans-venous permanent pacemaker implantation: No superior vena cava access or mechanical tricuspid valve.
  6. Pregnancy or breastfeeding.
  7. No affiliation to a social security scheme.
  8. Refusal to participate or withdrawal of informed consent.
  9. Incapacity to consent.
  10. Adults under legal protection (trusteeship, guardianship, curatorship).

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Left bundle branch area pacing with pacemaker and conduction system pacing (AMVIA SKY DR-T device)

LBB(AP) procedure will be performed by experienced operators according international guidelines and expert consensus. The implantation technique will be those used routinely in these expert centers.

The procedure will begin with a vein access (axillary, sub-clavian or cephalic). The atrial, if necessary, will be implanted as usual practice. LBB(AP) lead will be implanted as recommended. LBB(AP) positioning criteria, as described in reference clinical studies, will be checked in order to differentiate between LBB(AP) and deep septal pacing.

Övrig: Implantable loop recorder for rhythm monitoring (ILR, Biotronik BIOMONITOR IV Device)

Control arm

ILR Procedure will be performed by experienced operators according international guidelines and expert consensus. The implantation technique will be those used routinely in these expert centers.

The implanted device will be a Biomonitor IV (Biotronik, Berlin, Germany) and next generation if necessary.

The implantable Loop Recorder is a single-lead ECG monitor of small size with long-term functionality (approximately 3 to 5 years). It is implanted under local anesthesia in the subcutaneous space of the left thoracic region (incision at the level of the 4th left intercostal space at a 45° angle).

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The first occurrence of one of the following events : hospitalization for worsening heart failure, episode of syncope or dizziness, high-grade atrioventricular conduction disturbance)
Tidsram: From randomization to 12 follow up

The primary efficacy endpoint is a composite clinical outcome evaluated at 12 months after randomization, defined as the first occurrence of one of the following events:

  1. Hospitalization for worsening heart failure,
  2. Episode of syncope or dizziness,
  3. High-grade atrioventricular conduction disturbance (second-degree AV block type II or third-degree AV block requiring implantation of a permanent pacemaker, documented > 3 seconds on ILR or ECG)).

The composite endpoint will be analyzed as time-to-event data with death considered as a competing risk.

From randomization to 12 follow up

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of atrial fibrillation, ventricular tachycardia, non-sustained ventricular tachycardia
Tidsram: At 6,12, 24 and 36 months after randomization
At 6,12, 24 and 36 months after randomization
Evolution of LVEF
Tidsram: At 6,12, 24 and 36 months after randomization

Measurement of LVEF at inclusion and at each follow-up time point. The change in LVEF over time will be assessed relative to the date of inclusion and the preceding time point.

At 6,12, 24 and 36 months after randomization
Evolution of Quality of life (EQ-5D)
Tidsram: At 6, 12, 24 and 36 months after randomization

Measurement of EQ-5D at inclusion and at each follow-up time point. The change in EQ-5D over time will be assessed relative to the date of inclusion and the preceding time point.

At 6, 12, 24 and 36 months after randomization
Incidence of Hospitalizations (all-cause, cardiovascular, HF-related)
Tidsram: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization
Incidence of Mortality (all-cause, cardiovascular, HF-related)
Tidsram: At 6, 12, 24 and 36 months after randomization

Measurement of the cumulative incidence of all-cause, cardiovascular, and heart failure-related mortality at 6, 12, 24, and 36 months after randomization, based on the occurrence and documented cause of death.

At 6, 12, 24 and 36 months after randomization
Medico-economic evaluation
Tidsram: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization
Complications related to pacemaker or ILR implantation
Tidsram: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization
Unscheduled pacemaker implantation in the ILR group
Tidsram: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

15 oktober 2026

Primärt slutförande (Beräknad)

15 oktober 2033

Avslutad studie (Beräknad)

15 oktober 2034

Studieregistreringsdatum

Först inskickad

6 oktober 2026

Först inskickad som uppfyllde QC-kriterierna

26 oktober 2026

Första postat (Faktisk)

2 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

13 november 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera